Brentuximab Vedotin in Early Stage Hodgkin Lymphoma (RADAR)

  • End date
    Sep 22, 2032
  • participants needed
  • sponsor
    University College, London
Updated on 7 October 2022
ejection fraction
chemotherapy regimen
classical hodgkin lymphoma


Eligible patients will be randomised to receive either ABVD or A2VD chemotherapy.

An interim PET-CT scan will be performed after 2 cycles of treatment, which will be used to adapt subsequent treatment. Patients will receive a total of 3-4 cycles of chemotherapy and may also receive involved site radiotherapy as consolidation.

Patients will be followed up for a minimum of 5 years after treatment.


Eligible patients will be randomised to receive either ABVD chemotherapy (doxorubicin, bleomycin, vinblastine and dacarbazine) or A2VD chemotherapy (doxorubicin, brentuximab vedotin, vinblastine and dacarbazine, with growth factor support).

If patients agree, they will have a PET-CT scan after 1 cycle (PET1). The result of this scan will be blinded and used for exploratory endpoints only. Treatment will not be influenced by the result of this scan.

All patients will have a PET-CT scan after 2 cycles of treatment (PET2) which will be centrally reviewed. The Deauville score from central review will be used to risk adapt subsequent therapy as follows:

  • Patients with Deauville score 1-3 will have one further cycle of their randomised chemotherapy and then enter follow up.
  • Patients with Deauville score 4 will have two further cycles of their randomised chemotherapy followed by involved site radiotherapy
  • Patients with Deauville score 5 will be withdrawn from trial treatment. They will have further treatment at their treating clinician's discretion and will enter follow up for the trial.

Patients with Deauville score 4 on PET2 will have a final PET-CT scan to confirm adequate treatment response.

Patients will be followed up for a minimum of 5 years after completing treatment.

Condition Hodgkin Lymphoma
Treatment Bleomycin, doxorubicin, dacarbazine, brentuximab vedotin, Vinblastine, Involved site radiotherapy, Haematopoietic growth factor
Clinical Study IdentifierNCT04685616
SponsorUniversity College, London
Last Modified on7 October 2022


Yes No Not Sure

Inclusion Criteria

Males and females aged 16-69 years (inclusive
Histologically confirmed classical Hodgkin lymphoma
Stage I or II supradiaphragmatic disease with no mediastinal bulk disease (defined as greater than a third of the transthoracic diameter at any level of thoracic vertebra as determined by CT) or B symptoms. Bulky disease at other sites is acceptable. Extranodal disease (single extranodal site (stage I) or contiguous nodal extension (stage II)) is acceptable
ECOG performance status 0-2
No previous treatment for Hodgkin lymphoma
Fit to receive anthracycline-based chemotherapy (patients with a history of ischaemic heart disease or hypertension should have a left ventricular ejection fraction of ≥50%)
Creatinine clearance (measured or calculated >40ml/min
Total bilirubin <1.5 x upper limit of normal, unless attributable to disease or known Gilbert's syndrome
ALT or AST < 2 x upper limit of normal
Adequate bone marrow function with neutrophils ≥1.0x10^9/l and platelets ≥100x10^9/l
Haemoglobin ≥8g/dL
Willing and able to comply with the requirements of the protocol, including contraceptive advice, where applicable
Written informed consent

Exclusion Criteria

Previous treatment for Hodgkin lymphoma, excluding short courses of oral corticosteroids at a dose of 100mg prednisolone (or equivalent) for up to 7 days
Infradiaphragmatic disease
Nodular lymphocyte predominant Hodgkin lymphoma
Absence of FDG-avid lesions on baseline PET scan
Age 70 years or over or age 15 years or under
Other cancer diagnosed with the last 5 years. Patients with completely excised carcinoma in situ of any type and basal or squamous cell carcinoma of the skin are not excluded
Recurrent or persistent other cancer within last 5 years irrespective of date of initial diagnosis
Pre-existing grade ≥1 sensory or motor neuropathy from any cause
History of or current progressive multi-focal leukoencephalopathy or other chronic condition of the brain
Symptomatic neurologic disease compromising normal activities of daily living or requiring medications
Infection with HIV, hepatitis C or active hepatitis B infection (surface antigen or DNA positive)
Any active systemic viral, bacterial or fungal infection requiring systemic antibiotics, antivirals or antifungals within 2 weeks prior to first trial drug dose
Receiving or recently treated with any other investigational agent (within 4 weeks of trial entry)
Pregnant or breastfeeding women
Known hypersensitivity to recombinant proteins, murine proteins, or to any excipient contained in the drug formulation of brentuximab vedotin or any component of ABVD
Known history of any cardiovascular or respiratory conditions that would preclude anthracycline or bleomycin administration
Other significant medical or psychiatric comorbidity that in the opinion of the investigator would make administration of ABVD or A2VD hazardous
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note